Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.2 USD | -4.21% | -6.15% | -31.17% |
Business Summary
Number of employees: 704
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutic Compounds
100.0
%
| 75 | 100.0 % | 397 | 100.0 % | +425.83% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 75 | 100.0 % | 397 | 100.0 % | +425.83% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
Caroline Baumal
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-01-02 |
Adam Townsend
COO | Chief Operating Officer | 47 | 18-11-19 |
Lukas Scheibler
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-03-31 |
Meredith Kaya
IRC | Investor Relations Contact | - | - |
Jeffrey Eisele
PRN | Corporate Officer/Principal | - | 19-12-31 |
Vahe Ghahraman
LAW | General Counsel | - | 19-03-31 |
Thomas Lackner
PRN | Corporate Officer/Principal | - | 19-01-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
Director/Board Member | 65 | 13-06-30 | |
Andrew Dunlop
BRD | Director/Board Member | 52 | 10-02-28 |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Founder | 54 | 09-09-24 | |
Lok Chung Chan
CHM | Chairman | 73 | 13-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 121,365,555 | 104,005,903 ( 85.70 %) | 0 | 85.70 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.10% | 5.22B | |
-2.47% | 89.37B | |
+2.76% | 40.65B | |
-12.23% | 32.81B | |
+52.41% | 25B | |
-17.36% | 15.29B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
+6.14% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- APLS Stock
- Company Apellis Pharmaceuticals, Inc.